1515 Wynkoop Street, Suite 600
Denver, CO 80202
Tim Worrall provides sophisticated and comprehensive patent strategies that are designed to achieve the business goals of his clients throughout the United States and internationally.
Tim helps clients protect innovation by developing and prosecuting sophisticated patent portfolios, assessing patent portfolios from both an investor-side and company-side due diligence perspective, and providing freedom to practice, non-infringement, and invalidity analysis. Tim focuses on developing patent portfolios that can be leveraged defensively to protect a client's existing innovation, and offensively to protect intellectual property in a broader commercial space. In the due diligence context, he assesses the strength and weakness of patent portfolios with an emphasis on providing strategic recommendations to address weakness and increase the portfolio's value. Tim's opinion practice focuses on creating value from intellectual property by developing strategies related to freedom to practice reviews, non-infringement and invalidity analysis, to identify and address threats from third-party patents.
Tim also works with licensing and transactional attorneys to leverage intellectual property assets. In particular, he works with transactional attorneys in out-license and in-license agreements, private equity and venture capital transactions, and mergers and acquisitions. Separately, Tim works closely with attorneys in litigation and regulatory practices to leverage and maximize intellectual property assets.
In the pharmaceutical and biotechnology sectors, Tim helps innovators protect and maximize the lifecycle of pharmaceuticals and biotechnology products, assays, and devices. His practice centers around developing and procuring national and worldwide patent portfolios that extend the value of developing technology. Tim works closely with attorneys in the patent litigation practice to develop portfolios capable of withstanding litigation, and with the firm's FDA practice to develop non-patent exclusivity.